Achilles Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. The Company Announced Interim Phase I/IIa Data on the Use of Clonal Neoantigen Reactive T Cells From the CHIRON Study in Advanced Unresectable or Metastatic Non-small Cell Lung Cancer and the THETIS Study in Recurrent or Metastatic Malignant Melanoma
Achilles Therapeutics公佈第四季度財務業績後，該公司股價走低。該公司公佈了關於使用克隆新抗原反應性T細胞的I/IIa期中期數據，這些數據來自CHIRON在晚期不可切除或轉移性非小細胞肺癌中的研究和針對複發性或轉移性惡性黑色素瘤的THETIS研究